Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by Analysts

Shares of Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $31.44.

Several brokerages have recently commented on EXEL. The Goldman Sachs Group raised Exelixis to a "strong sell" rating in a report on Tuesday, October 15th. Stifel Nicolaus increased their target price on Exelixis from $26.00 to $30.00 and gave the stock a "hold" rating in a report on Wednesday, October 16th. Wells Fargo & Company lifted their price target on Exelixis from $32.00 to $36.00 and gave the company an "overweight" rating in a report on Wednesday, October 30th. Piper Sandler increased their price objective on shares of Exelixis from $33.00 to $36.00 and gave the stock an "overweight" rating in a report on Wednesday, October 30th. Finally, Bank of America upped their target price on shares of Exelixis from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Tuesday, October 15th.

Insider Buying and Selling

In other news, EVP Dana Aftab sold 1,162 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total transaction of $36,486.80. Following the transaction, the executive vice president now directly owns 498,945 shares of the company's stock, valued at approximately $15,666,873. This trade represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the business's stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $26.38, for a total value of $659,500.00. Following the completion of the sale, the executive vice president now owns 605,325 shares of the company's stock, valued at approximately $15,968,473.50. This trade represents a 3.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 339,736 shares of company stock valued at $11,508,610. Company insiders own 2.85% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Covestor Ltd increased its holdings in Exelixis by 5.7% in the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company's stock valued at $164,000 after buying an additional 341 shares during the period. Resonant Capital Advisors LLC boosted its holdings in shares of Exelixis by 3.6% in the 2nd quarter. Resonant Capital Advisors LLC now owns 13,746 shares of the biotechnology company's stock valued at $309,000 after purchasing an additional 477 shares in the last quarter. Cornercap Investment Counsel Inc. increased its stake in shares of Exelixis by 1.1% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 50,497 shares of the biotechnology company's stock valued at $1,135,000 after purchasing an additional 539 shares during the last quarter. Creative Planning raised its holdings in shares of Exelixis by 0.8% during the 2nd quarter. Creative Planning now owns 71,700 shares of the biotechnology company's stock worth $1,611,000 after buying an additional 548 shares in the last quarter. Finally, Advisors Asset Management Inc. boosted its stake in Exelixis by 3.2% in the third quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company's stock valued at $515,000 after buying an additional 609 shares in the last quarter. Institutional investors own 85.27% of the company's stock.

Exelixis Stock Performance

Shares of EXEL stock traded up $0.05 during mid-day trading on Wednesday, reaching $35.28. The company's stock had a trading volume of 776,348 shares, compared to its average volume of 2,055,064. The firm's 50-day moving average is $32.13 and its two-hundred day moving average is $26.87. Exelixis has a 1-year low of $19.20 and a 1-year high of $36.97. The company has a market cap of $10.08 billion, a P/E ratio of 22.58, a PEG ratio of 0.90 and a beta of 0.52.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating analysts' consensus estimates of $0.36 by $0.04. The company had revenue of $539.50 million for the quarter, compared to the consensus estimate of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company's quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 earnings per share. Sell-side analysts anticipate that Exelixis will post 1.69 EPS for the current year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.